发布求助
文献互助 智能选刊 最新文献

Neurodegenerative disease management最新文献

筛选
英文 中文
An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease. 帕金森病中 LRRK2 基因突变的全球分布概况。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-12-01 Epub Date: 2024-02-02 DOI: 10.2217/nmt-2023-0025
Hicham El Otmani, Mohamed Daghi, Nadia Tahiri Jouti, Suzanne Lesage
{"title":"An overview of the worldwide distribution of <i>LRRK2</i> mutations in Parkinson's disease.","authors":"Hicham El Otmani, Mohamed Daghi, Nadia Tahiri Jouti, Suzanne Lesage","doi":"10.2217/nmt-2023-0025","DOIUrl":"10.2217/nmt-2023-0025","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a neurodegenerative disorder with significant genetic influence. The <i>LRRK2</i> gene is a major genetic contributor, particularly the Gly2019Ser mutation. This focused review investigates the global distribution of <i>LRRK2</i> mutations, with emphasis on Gly2019Ser and other pathogenic variants. Prevalence rates of Gly2019Ser are highest in North Africa and the Ashkenazi-Jewish population, indicating a potential common ancestor and founder effect. Other <i>LRRK2</i> mutations, including Asn1437His, Arg1441Gly/Cys/His, Tyr1699Cys and Ile2020Thr, exhibit varying global prevalences. Understanding these distributions enhances our knowledge of PD genetics and aids personalized medicine. Further research is crucial to unravel clinical implications and develop targeted therapies for <i>LRRK2</i> mutation carriers.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"335-350"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Free-Cog revisited: the diagnostic contribution of cognitive and executive function. 重新审视 Free-Cog：认知和执行功能对诊断的贡献。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-12-01 Epub Date: 2024-01-24 DOI: 10.2217/nmt-2023-0013
Andrew J Larner, Alistair Burns
{"title":"Free-Cog revisited: the diagnostic contribution of cognitive and executive function.","authors":"Andrew J Larner, Alistair Burns","doi":"10.2217/nmt-2023-0013","DOIUrl":"10.2217/nmt-2023-0013","url":null,"abstract":"<p><p><b>Aim:</b> To examine Free-Cog, a recently described, hybrid screening instrument, as separate tests of cognitive (Free-Cog-Cog) and executive function (Free-Cog-Exec) to see if this improved screening accuracy for cognitive impairment compared with standard Free-Cog. <b>Materials & methods:</b> Free-Cog-Cog and Free-Cog-Exec were combined using Boolean logical 'AND' and 'OR' operators (serial and parallel combination), and also used to construct a stepwise decision tree. <b>Results:</b> Serial combination improved specificity and positive predictive value whereas parallel combination improved sensitivity, typical findings with these operators. Stepwise application identified groups with high and low probability of cognitive impairment but failed to differentiate adequately those in the intermediate uncertain diagnosis group. <b>Conclusion:</b> Study findings suggest limited benefit from reformulations of Free-Cog compared with the standard instrument.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"315-321"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139542855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
People with neuromuscular diseases and their relatives' perspectives on challenges in everyday life and healthcare. 神经肌肉疾病患者及其亲属对日常生活和医疗挑战的看法。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-12-11 DOI: 10.2217/nmt-2023-0008
Charlotte Handberg, Ulla Werlauff
{"title":"People with neuromuscular diseases and their relatives' perspectives on challenges in everyday life and healthcare.","authors":"Charlotte Handberg, Ulla Werlauff","doi":"10.2217/nmt-2023-0008","DOIUrl":"https://doi.org/10.2217/nmt-2023-0008","url":null,"abstract":"<p><p><b>Objective:</b> People with a neuromuscular disease (NMD) often experience challenges in everyday life and healthcare. <b>Aim:</b> To investigate experiences of and perspectives on challenges in everyday life and healthcare of people with NMDs and their relatives to gain new insights into how life-long rehabilitation can be tailored. <b>Patients & methods:</b> The design was qualitative using the interpretive description methodology and the Sense of Coherence theory. An ethnographic fieldwork was conducted where 45 persons with NMD and their relatives were included for interviews and participant observations. <b>Results & conclusion:</b> People with NMDs continually adapt to a changing functioning and balance their need for knowledge with their dependency on help when navigating the healthcare system. Structured, professionally facilitated peer support is needed.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 5","pages":"289-302"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment. 拼凑阿尔茨海默氏症的拼图：莱卡单抗在治疗中的作用。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-12-12 DOI: 10.2217/nmt-2023-0026
Danish Ali Ashraf, Hassan Tariq, Fathimath Shahaa Hassan, Farooq Kamran, Warda Mushtaq Khosa, Maha Mushtaq Khosa
{"title":"Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment.","authors":"Danish Ali Ashraf, Hassan Tariq, Fathimath Shahaa Hassan, Farooq Kamran, Warda Mushtaq Khosa, Maha Mushtaq Khosa","doi":"10.2217/nmt-2023-0026","DOIUrl":"https://doi.org/10.2217/nmt-2023-0026","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 5","pages":"257-259"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. 关于评估克拉利宾片对复发性多发性硬化症患者的长期疗效的简明摘要：CLASSIC-MS 研究。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-08-03 DOI: 10.2217/nmt-2023-0018
Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi, Elisabetta Verdun di Cantogno
{"title":"A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.","authors":"Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi, Elisabetta Verdun di Cantogno","doi":"10.2217/nmt-2023-0018","DOIUrl":"10.2217/nmt-2023-0018","url":null,"abstract":"<p><strong>What is this summary about?: </strong>Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies.</p><p><strong>What were the results?: </strong>Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS.</p><p><strong>What do the results mean?: </strong>The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"261-268"},"PeriodicalIF":2.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients. 复发缓解型多发性硬化症患者使用预填充醋酸格拉默笔的满意度和实用性。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-11-01 DOI: 10.2217/nmt-2022-0031
Herbert Schreiber, Joachim Hipp, Fabian Roßnagel, Christiane Moritz
{"title":"Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.","authors":"Herbert Schreiber, Joachim Hipp, Fabian Roßnagel, Christiane Moritz","doi":"10.2217/nmt-2022-0031","DOIUrl":"10.2217/nmt-2022-0031","url":null,"abstract":"<p><p><b>Aim:</b> Evaluation of practicality and patient satisfaction of a glatiramer acetate (GA) prefilled pen in patients with relapsing-remitting multiple sclerosis (RRMS). <b>Patients & methods:</b> A cross-sectional, multicenter, observational study evaluating patients' experiences with the GA-pen 3 months after its first use by means of self-reporting questionnaires. Primary end point was the proportion of patients who were satisfied with the pen. <b>Results:</b> 80 patients participated in the study. The majority (83.7%) was satisfied with the pen and 95% rated its application as easy or very easy. <b>Conclusion:</b> Most patients were satisfied with the GA-pen and rated its application as easy or very easy. Among the 12 device features, starting the injection without an injection button was considered the most appreciated feature. Improvements in pen functionality and design might allow patients to overcome many difficulties with self-injection, even those leading to nonadherence. But, this hypothesis awaits further validation by real-world follow-up studies.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"281-288"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71425414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of diagnostic routines for suspected Alzheimer's disease patients in US-American and German primary care. 美国和德国基层医疗机构对疑似阿尔茨海默病患者的诊断程序比较。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-12-08 DOI: 10.2217/nmt-2023-0023
Felix Menne, Timo Grimmer, Carola G Schipke
{"title":"Comparison of diagnostic routines for suspected Alzheimer's disease patients in US-American and German primary care.","authors":"Felix Menne, Timo Grimmer, Carola G Schipke","doi":"10.2217/nmt-2023-0023","DOIUrl":"https://doi.org/10.2217/nmt-2023-0023","url":null,"abstract":"<p><p><b>Aim:</b> Thorough diagnostics are a prerequisite for the optimal treatment of Alzheimer's disease (AD). Biomarker-based diagnostics are standard in academia, data on practitioners' diagnostic workups is scarce. <b>Materials & methods:</b> Surveys in German and US healthcare providers (HCP) were conducted regarding diagnostics in presumed AD patients. A subsample of 153 German and 88 US professionals was analyzed in detail. <b>Results:</b> Fewer German physicians conduct AD diagnostics themselves compared with US colleagues (67% vs 99%; p < 0.0001). German doctors more often order diagnostics at other institutions (65% vs 45%; p < 0.005). No significant differences were found regarding the type of diagnostics ordered at other institutions. <b>Conclusion:</b> Diagnostic routines for suspected AD patients differ between German and US-American healthcare providers.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 5","pages":"269-280"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. 醋酸格拉替默或IFN-β桥接疗法在计划妊娠的复发性多发性硬化症妇女中的应用
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2022-0032
Kerstin Hellwig, Sandra Thiel, Sabrina Haben, Andrea I Ciplea, Anna Kurzeja
{"title":"Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy.","authors":"Kerstin Hellwig,&nbsp;Sandra Thiel,&nbsp;Sabrina Haben,&nbsp;Andrea I Ciplea,&nbsp;Anna Kurzeja","doi":"10.2217/nmt-2022-0032","DOIUrl":"https://doi.org/10.2217/nmt-2022-0032","url":null,"abstract":"<p><p><b>Aim:</b> To assess bridging glatiramer acetate (GA) or IFN-β for relapse prevention in women with relapsing multiple sclerosis planning pregnancy. <b>Materials & methods:</b> Participants discontinued disease-modifying therapies (DMTs) and received GA/IFN (early- or delayed-start) or no DMT (control) until pregnancy. <b>Results:</b> Annualized relapse rate was lower in delayed-start GA/IFN cohort versus control during washout/bridging. During washout/bridging, bridging with GA/IFN in this cohort reduced clinical activity, while disease activity increased in controls versus baseline. <b>Conclusion:</b> More data on GA/IFN bridging are needed. Women with low relapsing multiple sclerosis activity in the year prior to DMT discontinuation due to pregnancy planning benefited from GA/IFN bridging with lower annualized relapse rate versus no treatment and reduced clinical activity versus baseline during washout/bridging and pregnancy.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"223-234"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9796752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computerized cognitive testing in patients with Parkinson's disease: an Indian perspective. 帕金森氏病患者的电脑认知测试:印度视角
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0002
Moulika Mandal, Kashish Srivastava
{"title":"Computerized cognitive testing in patients with Parkinson's disease: an Indian perspective.","authors":"Moulika Mandal,&nbsp;Kashish Srivastava","doi":"10.2217/nmt-2023-0002","DOIUrl":"https://doi.org/10.2217/nmt-2023-0002","url":null,"abstract":"<p><p><b>Aim:</b> This study investigates perspectives on computer-based assessments among elderly individuals with Parkinson's disease (PD) in India for more efficient usability of digital assessments for this population. <b>Materials & methods:</b> Content analysis was conducted on 30 participants diagnosed with PD, who were interviewed for their preferences and perspectives on integrating technology in healthcare assessments. <b>Results:</b> Elderly individuals with PD in India favored paper-pencil assessments over computer-based alternatives due to limited technological familiarity, resistance to change, lack of trust in healthcare technology and PD-related motor challenges. <b>Conclusion:</b> Elderly patients with Parkinson's in India indicated their discomfort with computer-based based cognitive assessment. Addressing barriers toward digital assessments in India is crucial for their successful implementation in healthcare.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"235-243"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10154383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease. 靶向代谢性谷氨酸受体治疗帕金森病。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0016
Philippe Huot
{"title":"Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease.","authors":"Philippe Huot","doi":"10.2217/nmt-2023-0016","DOIUrl":"https://doi.org/10.2217/nmt-2023-0016","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"203-206"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10173261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信